Surgery Partners (NASDAQ:SGRY) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other equities research analysts also recently commented on SGRY. ValuEngine downgraded shares of Surgery Partners from a “hold” rating to a “sell” rating in a report on Sunday, December 31st. Zacks Investment Research upgraded shares of Surgery Partners from a “sell” rating to a “hold” rating in a report on Saturday, January 13th. Benchmark set a $19.00 price target on shares of Surgery Partners and gave the stock a “buy” rating in a report on Tuesday, January 30th. Jefferies Group set a $18.00 price target on shares of Surgery Partners and gave the stock a “buy” rating in a report on Thursday, March 1st. Finally, Stifel Nicolaus lowered their price target on shares of Surgery Partners from $17.00 to $15.00 and set a “sell” rating for the company in a report on Tuesday, April 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $18.29.

Shares of NASDAQ SGRY opened at $15.70 on Friday. The stock has a market cap of $805.02, a PE ratio of -18.69 and a beta of 1.82. Surgery Partners has a 12 month low of $7.10 and a 12 month high of $24.05. The company has a quick ratio of 1.71, a current ratio of 1.86 and a debt-to-equity ratio of 1.59.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings results on Thursday, March 1st. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.11). The firm had revenue of $460.30 million for the quarter, compared to analysts’ expectations of $438.30 million. Surgery Partners had a negative return on equity of 0.53% and a negative net margin of 4.54%. The business’s quarterly revenue was up 50.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.35 earnings per share. research analysts predict that Surgery Partners will post -0.14 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Birch Grove Capital LP grew its holdings in Surgery Partners by 37.3% in the fourth quarter. Birch Grove Capital LP now owns 66,605 shares of the company’s stock valued at $806,000 after purchasing an additional 18,100 shares during the period. Royce & Associates LP grew its holdings in Surgery Partners by 55.3% in the fourth quarter. Royce & Associates LP now owns 1,058,668 shares of the company’s stock valued at $12,810,000 after purchasing an additional 377,086 shares during the period. Clearbridge Investments LLC grew its holdings in Surgery Partners by 12.6% in the fourth quarter. Clearbridge Investments LLC now owns 2,715,434 shares of the company’s stock valued at $32,857,000 after purchasing an additional 304,102 shares during the period. JPMorgan Chase & Co. grew its holdings in Surgery Partners by 156.0% in the third quarter. JPMorgan Chase & Co. now owns 524,775 shares of the company’s stock valued at $5,379,000 after purchasing an additional 319,775 shares during the period. Finally, Aperio Group LLC purchased a new stake in Surgery Partners in the fourth quarter valued at approximately $173,000.

About Surgery Partners

Surgery Partners, Inc is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services; Ancillary Services; and Optical Services.

Analyst Recommendations for Surgery Partners (NASDAQ:SGRY)

Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.